Catalent Pharma Solutions Signs Agreement with ALK-Abello to Expand Zydis Production Capacity

Catalent Pharma Solutions, Inc and Danish pharmaceutical company
ALK-Abello A/S have signed an agreement that will enable a substantial
increase in Zydis(R) oral dissolving tablet production capacity
dedicated to ALK-Abello's immunotherapy products.

Under the agreement, ALK-Abello will fund a new production line
for current and future tablet-based allergy products, which will be
based at Catalent's Swindon, United Kingdom facility. Commercial
production on the new line is currently expected to begin in 2010.

ALK-Abello has launched GRAZAX(R), a tablet-based vaccine against
grass pollen allergy, using Catalent's innovative Zydis oral
dissolving tablet technology, and Catalent is already producing the
Zydis formulation of GRAZAX in the Swindon facility.

"We are pleased to have reached this next important step in our
relationship with ALK-Abello, which began more than four years ago,"
commented Thomas Stuart, group president of Oral Technologies for
Catalent. "The clinical success of GRAZAX(R) demonstrates that
protein-based products such as allergens can be taken orally by
patients rather than via injection, and we believe Zydis provides
unique advantages to deliver these and other types of novel compounds.
We look forward to supporting the further success of GRAZAX(R) and
additional ALK-Abello immunotherapy products."

"We are pleased to have reached this agreement with Catalent to
provide important new production capacity, which we believe will be
required to meet the expected future demand for our tablet-based
allergy vaccines," said Jens Bager, president and CEO of ALK-Abello.
"We appreciate the consistent performance and dedication of the
Catalent team in Swindon, and the valuable contribution the team and
the Zydis technology is making to our product."

Catalent is the world leader in providing advanced dose form
delivery technologies to the industry. Zydis, Catalent's fast
dissolving oral tablet used in GRAZAX, can be swallowed without water
and dissolves in the mouth in typically less than three seconds. Zydis
offers the potential for added patient and consumer convenience,
enhanced drug performance, and improved patient compliance. In
addition to the Swindon, United Kingdom facility, Catalent has also
recently established commercial-scale Zydis production in New Jersey.

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions
is the leading provider of advanced technologies, and development,
manufacturing and packaging services for pharmaceutical, biotechnology
and consumer healthcare companies in nearly 100 countries. Catalent
applies its local market expertise and technical creativity to advance
treatments, change markets and enhance patient outcomes. Catalent
employs approximately 10,000 at more than 30 facilities worldwide and
generates more than $1.7 billion of annual revenue. For more
information, visit www.catalent.com.